Top ▲
GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
Gene and Protein Information ![]() |
|||||||
Species | TM | P Loops | AA | Chromosomal Location | Gene Symbol | Gene Name | Reference |
Human | 3 | 1 | 1484 | 12p13.1 | GRIN2B | glutamate ionotropic receptor NMDA type subunit 2B | |
Mouse | 3 | 1 | 1482 | 6 66.38 cM | Grin2b | glutamate receptor, ionotropic, NMDA2B (epsilon 2) | |
Rat | 3 | 1 | 1482 | 4q43 | Grin2b | glutamate ionotropic receptor NMDA type subunit 2B |
Previous and Unofficial Names ![]() |
NMDAR2B | GluRepsilon2 | glutamate receptor, ionotropic, N-methyl D-aspartate 2B | glutamate receptor, ionotropic, NMDA2B (epsilon 2) | glutamate receptor |
Database Links ![]() |
|
Alphafold | Q13224 (Hs), Q01097 (Mm), Q00960 (Rn) |
ChEMBL Target | CHEMBL1904 (Hs), CHEMBL3442 (Mm), CHEMBL311 (Rn) |
DrugBank Target | Q13224 (Hs), Q13224 (Hs) |
Ensembl Gene | ENSG00000273079 (Hs), ENSMUSG00000030209 (Mm), ENSRNOG00000008766 (Rn) |
Entrez Gene | 2904 (Hs), 14812 (Mm), 24410 (Rn) |
Human Protein Atlas | ENSG00000273079 (Hs) |
KEGG Gene | hsa:2904 (Hs), mmu:14812 (Mm), rno:24410 (Rn) |
OMIM | 138252 (Hs) |
Orphanet | ORPHA266126 (Hs) |
Pharos | Q13224 (Hs) |
RefSeq Nucleotide | NM_000834 (Hs), NM_008171 (Mm), NM_012574 (Rn) |
RefSeq Protein | NP_000825 (Hs), NP_032197 (Mm), NP_036706 (Rn) |
UniProtKB | Q13224 (Hs), Q01097 (Mm), Q00960 (Rn) |
Wikipedia | GRIN2B (Hs) |
Selected 3D Structures ![]() |
|||||||||||||
![]() |
|
||||||||||||
![]() |
|
Natural/Endogenous Ligands ![]() |
D-aspartic acid |
D-serine |
glycine |
L-aspartic acid |
L-glutamic acid |
Download all structure-activity data for this target as a CSV file
Agonists | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Key to terms and symbols | View all chemical structures | Click column headers to sort | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Antagonists | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Key to terms and symbols | View all chemical structures | Click column headers to sort | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Channel Blockers | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Key to terms and symbols | View all chemical structures | Click column headers to sort | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Allosteric Modulators | ||||||||||||||||||||||||||||||||||||||||||||||
Key to terms and symbols | View all chemical structures | Click column headers to sort | ||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||
View species-specific allosteric modulator tables |
Other Binding Ligands | ||||||||||||||||||||
Key to terms and symbols | Click column headers to sort | |||||||||||||||||||
|
Clinically-Relevant Mutations and Pathophysiology ![]() |
||||||||||||||
|
1. Štefková-Mazochová K, Danda H, Dehaen W, Jurásek B, Šíchová K, Pinterová-Leca N, Mazoch V, Krausová BH, Kysilov B, Smejkalová T et al.. (2022) Pharmacokinetic, pharmacodynamic, and behavioural studies of deschloroketamine in Wistar rats. Br J Pharmacol, 179 (1): 65-83. [PMID:34519023]
2. Acker TM, Yuan H, Hansen KB, Vance KM, Ogden KK, Jensen HS, Burger PB, Mullasseril P, Snyder JP, Liotta DC et al.. (2011) Mechanism for noncompetitive inhibition by novel GluN2C/D N-methyl-D-aspartate receptor subunit-selective modulators. Mol Pharmacol, 80 (5): 782-95. [PMID:21807990]
3. Anderson DR, Volkmann RA, Menniti FS. (2019) N-alkylaryl-5-oxyaryl-octahydro-cyclopenta[c]pyrrole negative allosteric modulators of NR2B. Patent number: US10239835B2. Assignee: Cadent Therapeutics Inc. Priority date: 26/09/2014. Publication date: 26/03/2019.
4. Auberson YP, Allgeier H, Bischoff S, Lingenhoehl K, Moretti R, Schmutz M. (2002) 5-Phosphonomethylquinoxalinediones as competitive NMDA receptor antagonists with a preference for the human 1A/2A, rather than 1A/2B receptor composition. Bioorg Med Chem Lett, 12 (7): 1099-102. [PMID:11909726]
5. Feng B, Tse HW, Skifter DA, Morley R, Jane DE, Monaghan DT. (2004) Structure-activity analysis of a novel NR2C/NR2D-preferring NMDA receptor antagonist: 1-(phenanthrene-2-carbonyl) piperazine-2,3-dicarboxylic acid. Br J Pharmacol, 141 (3): 508-16. [PMID:14718249]
6. Frizelle PA, Chen PE, Wyllie DJ. (2006) Equilibrium constants for (R)-[(S)-1-(4-bromo-phenyl)-ethylamino]-(2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-yl)-methyl]-phosphonic acid (NVP-AAM077) acting at recombinant NR1/NR2A and NR1/NR2B N-methyl-D-aspartate receptors: Implications for studies of synaptic transmission. Mol Pharmacol, 70 (3): 1022-32. [PMID:16778008]
7. Hill MD, Blanco MJ, Salituro FG, Bai Z, Beckley JT, Ackley MA, Dai J, Doherty JJ, Harrison BL, Hoffmann EC et al.. (2022) SAGE-718: A First-in-Class N-Methyl-d-Aspartate Receptor Positive Allosteric Modulator for the Potential Treatment of Cognitive Impairment. J Med Chem, 65 (13): 9063-9075. [PMID:35785990]
8. Karakas E, Furukawa H. (2014) Crystal structure of a heterotetrameric NMDA receptor ion channel. Science, 344 (6187): 992-7. [PMID:24876489]
9. Karakas E, Simorowski N, Furukawa H. (2011) Subunit arrangement and phenylethanolamine binding in GluN1/GluN2B NMDA receptors. Nature, 475 (7355): 249-53. [PMID:21677647]
10. Morley RM, Tse HW, Feng B, Miller JC, Monaghan DT, Jane DE. (2005) Synthesis and pharmacology of N1-substituted piperazine-2,3-dicarboxylic acid derivatives acting as NMDA receptor antagonists. J Med Chem, 48 (7): 2627-37. [PMID:15801853]
11. Myers SJ, Ruppa KP, Wilson LJ, Tahirovic YA, Lyuboslavsky P, Menaldino DS, Dentmon ZW, Koszalka GW, Zaczek R, Dingledine RJ et al.. (2021) A Glutamate N-Methyl-d-Aspartate (NMDA) Receptor Subunit 2B-Selective Inhibitor of NMDA Receptor Function with Enhanced Potency at Acidic pH and Oral Bioavailability for Clinical Use. J Pharmacol Exp Ther, 379 (1): 41-52. [PMID:34493631]
12. Neyton J, Paoletti P. (2006) Relating NMDA receptor function to receptor subunit composition: limitations of the pharmacological approach. J Neurosci, 26 (5): 1331-3. [PMID:16452656]
Bettler B, Collingridge GL, Dingledine R, Heinemann SF, Hollmann M, Lerma J, Lodge D, Mayer M, Mishina M, Mulle C, Nakanishi S, Olsen R, Peineau S, Peters JA, Seeburg P, Spedding M, Watkins JC. Ionotropic glutamate receptors in GtoPdb v.2023.1. IUPHAR/BPS Guide to Pharmacology CITE. 2023; 2023(1). Available from: https://doi.org/10.2218/gtopdb/F75/2023.1.